Correlation Between Eliem Therapeutics and Entrada Therapeutics

Can any of the company-specific risk be diversified away by investing in both Eliem Therapeutics and Entrada Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eliem Therapeutics and Entrada Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Eliem Therapeutics and Entrada Therapeutics, you can compare the effects of market volatilities on Eliem Therapeutics and Entrada Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eliem Therapeutics with a short position of Entrada Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eliem Therapeutics and Entrada Therapeutics.

Diversification Opportunities for Eliem Therapeutics and Entrada Therapeutics

-0.89

Correlation Coefficient

Eliem Therapeutics  Entrada Therapeutics

Pay attention - limited upside

The 3 months correlation between Eliem and Entrada is -0.89. Overlapping area represents the amount of risk that can be diversified away by holding Eliem Therapeutics and Entrada Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Entrada Therapeutics and Eliem Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eliem Therapeutics are associated (or correlated) with Entrada Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Entrada Therapeutics has no effect on the direction of Eliem Therapeutics i.e., Eliem Therapeutics and Entrada Therapeutics go up and down completely randomly.

Pair Corralation between Eliem Therapeutics and Entrada Therapeutics

Given the investment horizon of 90 days Eliem Therapeutics is expected to under-perform the Entrada Therapeutics. In addition to that, Eliem Therapeutics is 1.62 times more volatile than Entrada Therapeutics. It trades about -0.3 of its total potential returns per unit of risk. Entrada Therapeutics is currently generating about 0.19 per unit of volatility. If you would invest  1,486  in Entrada Therapeutics on September 12, 2024 and sell it today you would earn a total of  565.00  from holding Entrada Therapeutics or generate 38.02% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Significant
Accuracy	93.75%
Values	Daily Returns

Eliem Therapeutics  vs.  Entrada Therapeutics

Eliem Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Eliem Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Entrada Therapeutics

Risk-Adjusted Performance

14 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Entrada Therapeutics are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak fundamental indicators, Entrada Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Eliem Therapeutics and Entrada Therapeutics

The main advantage of trading using opposite Eliem Therapeutics and Entrada Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eliem Therapeutics position performs unexpectedly, Entrada Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entrada Therapeutics will offset losses from the drop in Entrada Therapeutics' long position.

The idea behind Eliem Therapeutics and Entrada Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.